Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: Results of the UNITE study

被引：0
|
作者：
Mcallister, Peter [1 ]
Campos, Verena Ramirez [2 ]
Roth-Ben Arie, Zipora [3 ]
Krasenbaum, Lynda [4 ]
Ning, Xiaoping [5 ]
Galic, Maja [6 ]
Mitsikostas, Dimos [7 ]
机构：
[1] New England Inst Neurol & Headache, Dept Neurol, Stamford, CT USA
[2] Teva Branded Pharmaceut Prod R&D Inc, Neurosci Headache & Movement Disorders, W Chester, PA USA
[3] Teva Pharmaceut Ind Ltd, Clin Operat, Petah Tiqwa, Israel
[4] Teva Branded Pharmaceut Prod R&D, Ta Migraine & Headache Global Med Affairs, W Chester, PA USA
[5] Teva Branded Pharmaceut Prod R&D, Cns Migraine Global Clin Dev, W Chester, PA USA
[6] TEVA PHARMA Prod Farmaceut Lda, Global Med Affairs, Porto Salvo, Portugal
[7] Natl & Kapodistrian Univ Athens, Dept Neurol 1, Athens, Greece
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2023年 / 455卷
关键词：
D O I：
10.1016/j.jns.2023.121660
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
121660
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder
    Rethorst, Chad D.
    South, Charles C.
    Rush, A. John
    Greer, Tracy L.
    Trivedi, Madhukar H.
    [J]. DEPRESSION AND ANXIETY, 2017, 34 (12) : 1116 - 1122
  • [22] ESCITALOPRAM IN TREATMENT OF DISABILITY IN MAJOR DEPRESSIVE PATIENTS
    Zivkovic, N.
    Pavicevic, D.
    Djokic, G.
    [J]. EUROPEAN PSYCHIATRY, 2010, 25
  • [23] Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study
    Dold, Markus
    Bartova, Lucie
    Souery, Daniel
    Mendlewicz, Julien
    Serretti, Alessandro
    Porcelli, Stefano
    Zohar, Joseph
    Montgomery, Stuart
    Kasper, Siegfried
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 91 : 1 - 13
  • [24] A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder
    Ren, Siyu
    Peng, He
    Zhang, Jinniu
    Yang, Jian
    He, Yi
    Sun, Zuoli
    Wang, Gang
    [J]. GENE, 2024, 926
  • [25] Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder
    Brecht, Stephan
    Kajdasz, Daniel
    Ball, Susan
    Thase, Michael E.
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (06) : 317 - 324
  • [26] Familial Dynamics and their Impact on Clinical Outcomes in Greek Patients with Major Depressive Disorder
    Koutra, Katerina
    Mavroeides, Georgios
    Paschalidou, Anna
    Roumeliotaki, Theano
    Basta, Maria
    Vgontzas, Alexandros N.
    [J]. INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION, 2024,
  • [27] Duloxetine for the treatment of major depressive disorder in elderly patients: Treatment outcomes in patients with comorbid arthritis
    Wohlreich, MM
    Mallinckrodt, C
    Chappell, A
    Myers, T
    Raskin, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 524 - 524
  • [28] The impact of fremanezumab treatment on depression severity in patients with concomitant antidepressant use: post hoc analysis of the UNITE study
    Barbanti, P.
    Tassorelli, C.
    Campos, V. Ramirez
    Krasenbaum, L. J.
    Akcicek, H.
    Ortega, M.
    Burstein, R.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [29] Impact of Antipsychotic Treatment Switching in Patients With Schizophrenia, Bipolar Disorder, And Major Depressive Disorder
    Carroll, Benjamin
    Ayyagari, Rajeev
    Thomason, Darren
    Mu, Fan
    Philbin, Michael
    [J]. NEUROLOGY, 2019, 92 (15)
  • [30] The impact of fremanezumab on headache-related disability in patients with chronic migraine using the Headache Impact Test
    Winner, Paul K.
    Fitzgerald, Timothy
    Gandhi, Sanjay K.
    Yeung, Paul P.
    Cohen, Joshua M.
    Ma, Yuju
    Aycardi, Ernesto
    [J]. JOURNAL OF HEADACHE AND PAIN, 2017, 18
12345